Senior Account (Business) Director job with Stonor
Senior Account (Business) Director in Agency, Health, Sales & Business Development, Marketing with Stonor. Apply Today.
Stay updated with breaking news from Digital Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Senior Account (Business) Director in Agency, Health, Sales & Business Development, Marketing with Stonor. Apply Today.
The blue-check validation from Twitter may only be adding to the confusion. Missy Voronyak, W2O Group managing director of social media and influencer activation, said the verified status implies more than just authentication. Blue-check Twitter accounts are commonly seen as official and even influential sources. “However, if they are providing disinformation—or not 'all of the information'—it can be confusing," Voronyak said via email. "The blue check mark on a social media account verifies that the author is who they claim to be, but it does not mean that everything they say is ac...
After a very public back-and-forth over COVID-19 vaccine supplies in Europe earlier this year, AstraZeneca said it would aim to deliver 40 million doses in the first quarter. It’s now rolling the estimate back to 30 million, Reuters reports—the same figure that triggered the initial controversy. Meanwhile, in some countries, doses are going unused.
Mar 11, 2021 12:08pm Who will lead the FDA under President Joe Biden? Former FDA chiefs are urging Biden to hurry up and make a choice. (FDA) The clock is ticking on an FDA commissioner nomination, with public pressure on President Joe Biden to pick up the pace. Six former FDA commissioners wrote the White House this week urging Biden to make a choice, according to several media reports. The letter, signed by Robert Califf, Scott Gottlieb, Margaret Hamburg, Jane Henney, Mark McClellan and Andrew von Eschenbach, pushed Biden to act in the face of the ongoing coronavirus pandemic. They noted v...
Europe's COVID-19 immunization campaign has been challenged by early supply problems and now safety concerns for AstraZeneca’s shot. A fourth vaccine is now on its way—though it's not going to fix the supply shortfall immediately.